Enzo Biochem (NYSE: ENZ) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $24.6 million.

For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.